Novartis’ US dosage-regimen patent 9,187,405 for Gilenya (fingolimod) 0.5mg capsules is not invalid and is also infringed by HEC Pharm’s proposed abbreviated new drug application product, a US district court has ordered, shooting down the potential for generic competition this year to the $1.8bn blockbuster.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?